Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

Stepping away from its billions-of-years-old role as a genetic blueprint, DNA is now embarking on a new journey as an active field agent within cells. This research by a team led by Professor Jongmin ...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0 This guideline consolidates all previous updates and reflects the body of evidence informing ...

The DECT NR+ vision and the ongoing redefinition of wireless audio and unified communication: What this means for AV and UC specifiers. When you purchase through links on our site, we may earn an ...

As CAR-T therapies continue to evolve, both viral and non-viral delivery systems are emerging as powerful platforms for ...